Mutations in genes encoding RNA splicing factors are the most common class of genetic alterations in myelodysplastic syndromes (MDS), a group of blood disorders that are characterized by clonal, dysplastic, and ineffective hematopoiesis. One of the most commonly mutated genes is SRSF2, which encodes a regulator of alternative splicing and is subject to recurrent missense mutations primarily affecting a single ?hotspot? residue. During the initial funding period of this grant, work by our labs and others led to a consensus model for how SRSF2 mutations promote MDS: MDS-associated hotspot SRSF2 mutations alter SRSF2?s RNA-binding affinity, driving mis-splicing of key hematopoietic regulators to cause dysplastic hematopoiesis. Importantly, SRSF2 mutations may confer therapeutically actionable vulnerabilities. We identified specific compounds that modulate RNA splicing to preferentially kill SRSF2-mutant cells over their wild-type counterparts, helping to motivate the earliest clinical trials of new drugs targeting MDS with splicing factor mutations. Here, we propose to refine and extend our current understanding of SRSF2 mutations. While useful, our current model is not sufficient to fully explain the genetic spectrum of SRSF2 mutations, interactions between SRSF2 mutations and other co-occurring genetic lesions, and the functional roles and therapeutic implications of SRSF2 mutations in MDS. Our interdisciplinary team consists of a physician-scientist with expertise in MDS and patient care (Abdel-Wahab) and a basic scientist with expertise in RNA splicing and functional genomics (Bradley). In preliminary studies, we identified diverse phenomena that are not explained by our current model of SRSF2 mutations: rare, non-hotspot SRSF2 mutations may be pathogenic; although multiple co-occurring splicing factor mutations are generally thought to be incompatible with cell survival, a subset of MDS patients carry two such mutations; SRSF2 mutations cause profound changes in RNA processing beyond mis-splicing of cassette exons; and SRSF2 mutations induce sensitivity to multiple classes of compounds that modulate RNA splicing via distinct mechanisms of action. We propose to build on these preliminary studies as follows:
Aim 1, Determine the molecular basis and functional consequences of widespread intron retention in SRSF2- mutant MDS;
Aim 2, Determine the biological and molecular basis for allele-specific interactions between SRSF2 mutations and additional genetic alterations in MDS;
Aim 3, Identify and test therapeutic strategies for targeting cells with spliceosomal gene mutations. The significance of these studies is that they will give insight into the molecular and functional basis for SRSF2 mutations in MDS. The health relatedness of this effort is that the proposed work may identify new treatment modalities that specifically target SRSF2-mutant MDS, which is associated with particularly poor prognosis.
Myelodysplastic syndromes (MDS) are a heterogeneous group of blood diseases, all of which are characterized by ineffective production of blood by the bone marrow. Here, we will investigate why mutations in the SRSF2 gene, which are commonly found in MDS, cause molecular changes within blood cells that result in ineffective blood production. We also seek to find new ways to treat MDS with SRSF2 mutations.
|Pineda, Jose Mario Bello; Bradley, Robert K (2018) Most human introns are recognized via multiple and tissue-specific branchpoints. Genes Dev 32:577-591|
|Yoshimi, Akihide; Abdel-Wahab, Omar (2018) Targeting mRNA Decapping in AML. Cancer Cell 33:339-341|
|Chang, Chan-Jung; Kotini, Andriana G; Olszewska, Malgorzata et al. (2018) Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs. Stem Cell Reports 10:1610-1624|
|Zarnegar, Sara; Durham, Benjamin H; Khattar, Pallavi et al. (2018) Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. Pediatr Blood Cancer 65:|
|Ozkaya, Neval; Rosenblum, Marc K; Durham, Benjamin H et al. (2018) The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort. Mod Pathol 31:581-597|
|Lee, Stanley Chun-Wei; North, Khrystyna; Kim, Eunhee et al. (2018) Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. Cancer Cell 34:225-241.e8|
|Papo, Matthias; Diamond, Eli L; Cohen-Aubart, Fleur et al. (2017) High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood 130:1007-1013|
|Durham, Benjamin H; Roos-Weil, Damien; Baillou, Claude et al. (2017) Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood 130:176-180|
|Micol, Jean-Baptiste; Pastore, Alessandro; Inoue, Daichi et al. (2017) ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nat Commun 8:15429|
|Taylor, Justin; Xiao, Wenbin; Abdel-Wahab, Omar (2017) Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood 130:410-423|
Showing the most recent 10 out of 24 publications